Home › Science › Biocon Chair: AI in Clinical Trials Is the Holy Grail
Science

Biocon Chair: AI in Clinical Trials Is the Holy Grail

Key Points

Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its current top-five global ranking. Speaking on the sidelines of the Bloomberg New Economy Forum in New Delhi, Mazumdar-Shaw added that while AI accelerates molecular discovery, the true "holy grail" is using the technology to abbreviate long, expensive clinical trials by...

Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its current top-five global ranking. Speaking on the sidelines of the Bloomberg New Economy Forum in New Delhi, Mazumdar-Shaw added that while AI accelerates molecular discovery, the true "holy grail" is using the technology to abbreviate long, expensive clinical trials by predicting safety and efficacy. (Source: Bloomberg)
Biocon Chair: AI (ORG) Kiran Mazumdar-Shaw (PERSON) Bloomberg (ORG) Francine Lacqua (PERSON) the Bloomberg New Economy Forum (ORG) New Delhi (LOCATION) Mazumdar-Shaw (ORG)
Originally published by Bloomberg Markets Read original →